<DOC>
	<DOCNO>NCT01112033</DOCNO>
	<brief_summary>In project , investigator aim study role biliverdin reductase A ( BLVRA ) HCV infect patient prior during/after standard antiviral therapy association viral clearance , disease progression treatment response comparison healthy subject .</brief_summary>
	<brief_title>Biliverdin Reductase A Chronic Hepatitis C Virus Infection</brief_title>
	<detailed_description>1 . To analyze biliverdin reductase ( BLVRA ) expression liver HVC infect patient undergo liver biopsy follow standard antiviral treatment ( peg-interferon plus ribavirin combination therapy ) patient form liver disease undergo liver biopsy control . 2 . To analyze BLVRA expression peripheral blood leukocyte ( PBL ) therapeutically naïve HCV patient , during/after standard antiviral therapy healthy control . 3 . To analyze BVLRA genetic polymorphism HCV infect patient healthy control .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<criteria>BLVRA expression study Therapeutically naïve HCV patient undergo antiviral treatment peginterferon plus ribavirin combination therapy BLVRA genetic polymorphism study HCV infect patient prior , , without antiviral therapy Coinfection HAV , HBV HIV Disorders heme metabolism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>biliverdin reductase</keyword>
	<keyword>BLVRA</keyword>
	<keyword>hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>peripheral blood mononuclear cell</keyword>
	<keyword>PBMC</keyword>
	<keyword>liver</keyword>
	<keyword>genetic polymorphism</keyword>
</DOC>